Publication | Closed Access

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Metastatic Breast CancerBreast OncologyMedicinePharmacologyBreast CancerPharmacotherapyCancer TreatmentOncologyCdk4/6 Inhibitor TreatmentEndocrine-related CancerUs Food